Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0FJ1I
|
||||
| Former ID |
DNC010912
|
||||
| Drug Name |
N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C25H23Cl3N2O3
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Potassium voltage-gated channel subfamily H member 2 | Target Info | Inhibitor | [1] | |
| Cannabinoid receptor 1 | Target Info | Inhibitor | [1] | ||
| Cannabinoid receptor 2 | Target Info | Inhibitor | [1] | ||
| KEGG Pathway | Rap1 signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Retrograde endocannabinoid signalinghsa04080:Neuroactive ligand-receptor interaction | |||||
| PANTHER Pathway | Endogenous cannabinoid signaling | ||||
| Pathway Interaction Database | N-cadherin signaling events | ||||
| PathWhiz Pathway | Muscle/Heart Contraction | ||||
| Reactome | Voltage gated Potassium channelsR-HSA-373076:Class A/1 (Rhodopsin-like receptors) | ||||
| G alpha (i) signalling eventsR-HSA-373076:Class A/1 (Rhodopsin-like receptors) | |||||
| G alpha (i) signalling events | |||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Hematopoietic Stem Cell Differentiation | |||||
| Potassium ChannelsWP455:GPCRs, Class A Rhodopsin-like | |||||
| Small Ligand GPCRs | |||||
| BDNF signaling pathway | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, OtherWP455:GPCRs, Class A Rhodopsin-like | |||||
| References | |||||
| REF 1 | Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4. Epub 2010 Apr 21.Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.